PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32733649-5 2020 We demonstrate that triptolide treatment of A549 and H460 NSCLC cells decreases Caveolin-1 (CAV-1) mRNA/protein expression, resulting in activation of the Akt/Bcl-2-mediated mitochondrial apoptosis pathway. triptolide 20-30 BCL2 apoptosis regulator Homo sapiens 159-164 32699295-0 2020 Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. triptolide 10-20 BCL2 apoptosis regulator Homo sapiens 111-116 32699295-9 2020 Together, these findings suggest that the regimen combining TPL and ABT-199 might be active against AML by inducing robust apoptosis through reciprocal regulation of anti- and proapoptotic Bcl-2 family proteins, therefore providing a strong rationale for the clinical investigation of this combination regimen for the treatment of AML. triptolide 60-63 BCL2 apoptosis regulator Homo sapiens 189-194 25875797-6 2015 In addition, triptolide decreased levels of HSP70, its transcription factor HSF1, as well as the antiapoptotic proteins Bcl-xL, Bcl-2, and Mcl-1, which are known to be up-regulated in pancreatic cancer. triptolide 13-23 BCL2 apoptosis regulator Homo sapiens 128-133 31115521-8 2019 Additionally, IL-6-induced activation of STAT3 target genes (e.g. MCL-1 and BCL-2) was attenuated by TP and homoharringtonine. triptolide 101-103 BCL2 apoptosis regulator Homo sapiens 76-81 27879593-11 2016 Interestingly, triptolide could increase the mixed chimerism level of recipients, possibly by inhibiting the apoptosis of transplanted bone marrow cells by means of regulation of the apoptotic genes bcl-2 and Bax. triptolide 15-25 BCL2 apoptosis regulator Homo sapiens 199-204 27999372-7 2016 Western blot analysis in vitro and in vivo showed that triptolide induced apoptotic protein Bax expression and inhibited phosph-NF-kappaB p65, Bcl-2 and VEGF proteins without affecting other NF-kappaB related protein expression. triptolide 55-65 BCL2 apoptosis regulator Homo sapiens 143-148 26107205-7 2015 High-dose triptolide showed a similar tumor-inhibitory effect as cisplatin (-50%); high-dose triptolide significantly inhibited Bcl-2 and VEGF expression in the xenograft model compared to normal saline control (P<0.05). triptolide 93-103 BCL2 apoptosis regulator Homo sapiens 128-133 25573072-6 2015 Combinatorial TP/HCPT treatment significantly enhanced the activation of caspase-3 and -9, Bax/Bcl-2 ratio, release of cytochrome c from mitochondrial and subsequent apoptosis. triptolide 14-16 BCL2 apoptosis regulator Homo sapiens 95-100 24880464-7 2014 Triptolide-induced apoptosis was accompanied by cytochrome c release and caspase-3 activation and was associated with downregulation of Bcl-2 and upregulation of Bax. triptolide 0-10 BCL2 apoptosis regulator Homo sapiens 136-141 24566325-9 2014 Finally, western blot analysis of triptolide-treated cells revealed the activation of caspase-3, caspase-9, PARP, and Bcl-2; this result demonstrated that triptolide induced apoptosis in gallbladder cancer cells by regulating apoptosis-related protein expression, and suggests that triptolide may be a promising drug to treat gallbladder carcinoma. triptolide 34-44 BCL2 apoptosis regulator Homo sapiens 118-123 24566325-9 2014 Finally, western blot analysis of triptolide-treated cells revealed the activation of caspase-3, caspase-9, PARP, and Bcl-2; this result demonstrated that triptolide induced apoptosis in gallbladder cancer cells by regulating apoptosis-related protein expression, and suggests that triptolide may be a promising drug to treat gallbladder carcinoma. triptolide 155-165 BCL2 apoptosis regulator Homo sapiens 118-123 24566325-9 2014 Finally, western blot analysis of triptolide-treated cells revealed the activation of caspase-3, caspase-9, PARP, and Bcl-2; this result demonstrated that triptolide induced apoptosis in gallbladder cancer cells by regulating apoptosis-related protein expression, and suggests that triptolide may be a promising drug to treat gallbladder carcinoma. triptolide 155-165 BCL2 apoptosis regulator Homo sapiens 118-123 19903580-5 2010 PG490 and 5-FU treatment induced activated caspase 3 and Bax expression and inhibited Bcl-2 expression. triptolide 0-5 BCL2 apoptosis regulator Homo sapiens 86-91 23900299-6 2013 Triptolide treatment resulted in a significant decrease in mRNA expression levels in genes encoding Bcl-2, cyclin D1, p27 and survivin and an increase in those encoding Bax and p21 in THP-1 cells. triptolide 0-10 BCL2 apoptosis regulator Homo sapiens 100-105 24772972-4 2013 Western blot analysis showed that the levels of procaspase-8, -9, Bcl-2, Bid and mitochondrial cytochrome c were downregulated in triptolide-treated U2OS cells, whereas the levels of Fas, FasL, Bax, cytosolic cytochrome c, cleaved caspase-3 and cleaved PARP were upregulated. triptolide 130-140 BCL2 apoptosis regulator Homo sapiens 66-71 19942343-4 2010 Triptolide induced abundant apoptosis with a prominent decline of Bcl-2, Bcl-X(L), survivin and Mcl-1. triptolide 0-10 BCL2 apoptosis regulator Homo sapiens 66-71 18379047-8 2008 Triptolide-induced apoptosis was accompanied by loss of mitochondrial membrane potential and release of cytochrome c (cyt-c) from the mitochondria to the cytosol and down-regulation of anti-apoptotic protein Bcl-2 levels with concurrent up-regulation in pro-apoptotic protein Bax levels and tumor suppressor protein p53 levels. triptolide 0-10 BCL2 apoptosis regulator Homo sapiens 208-213 16316721-0 2006 Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells. triptolide 0-10 BCL2 apoptosis regulator Homo sapiens 19-24 16316721-5 2006 Importantly, triptolide induced the appearance of a truncated 23kD Bcl-2 which was inhibited by the general caspase inhibitor Z-VAD-FMK. triptolide 13-23 BCL2 apoptosis regulator Homo sapiens 67-72 16316721-7 2006 On the other hand, transfected cells overexpressing the 28kD Bcl-2 became more resistant to triptolide and upon triptolide treatment accumulated in the G(1) instead of S phase. triptolide 92-102 BCL2 apoptosis regulator Homo sapiens 61-66 16316721-7 2006 On the other hand, transfected cells overexpressing the 28kD Bcl-2 became more resistant to triptolide and upon triptolide treatment accumulated in the G(1) instead of S phase. triptolide 112-122 BCL2 apoptosis regulator Homo sapiens 61-66 16316721-10 2006 Our data suggest that in the absence of an intact p53 and without altering Bax level triptolide induces apoptosis activates a positive amplification loop involving caspase-mediated Bcl-2 cleavage/activation, mitochondrial cytochrome c release and further activation of caspases. triptolide 85-95 BCL2 apoptosis regulator Homo sapiens 181-186 17900403-8 2007 The dose-dependent inhibition of cell proliferation and induction of apoptosis by triptolide may involve upregulation of Bax and downregulation of Bcl-2. triptolide 82-92 BCL2 apoptosis regulator Homo sapiens 147-152 16385419-8 2006 Overexpression of Bcl-2 in HeLa cells substantially attenuated triptolide-induced apoptosis. triptolide 63-73 BCL2 apoptosis regulator Homo sapiens 18-23 12508653-4 2002 Immunohistochemistry was used to examine the expression of Bax, Bcl-2 after treatment of triptolide and celastrol. triptolide 89-99 BCL2 apoptosis regulator Homo sapiens 64-69 12508653-7 2002 CONCLUSION: Triptolide and celastrol inhibit the proliferation of glioma cells in vitro, which was associated with promoting the expression of Bax and inhibiting the expression of Bcl-2 and accelerating cell apotosis. triptolide 12-22 BCL2 apoptosis regulator Homo sapiens 180-185 34915630-11 2021 The survival fraction (0.462) and protein level of Bcl-2 (0.44+-0.04) in the triptolide group were lower than those of the control group (0.702 and 0.93+-0.09, P<0.05). triptolide 77-87 BCL2 apoptosis regulator Homo sapiens 51-56